|Bid||61.69 x 1200|
|Ask||61.77 x 1800|
|Day's Range||61.15 - 63.86|
|52 Week Range||40.68 - 63.86|
|Beta (5Y Monthly)||1.46|
|PE Ratio (TTM)||33.91|
|Earnings Date||Feb 26, 2020|
|Forward Dividend & Yield||0.90 (1.50%)|
|Ex-Dividend Date||Feb 26, 2020|
|1y Target Est||59.88|
Perrigo Company plc (NYSE; TASE: PRGO) and its partner, Catalent Pharma Solutions, today announced that the U.S. Food and Drug Administration (FDA) has approved Perrigo's abbreviated new drug application for generic albuterol sulfate inhalation aerosol, the first AB-rated generic version of ProAir® HFA*. Perrigo is launching a limited quantity of generic albuterol sulfate inhalation aerosol and, in collaboration with its development and manufacturing partner Catalent, is ramping up production to meet future demand.
Plackers®, the nation's leading dental flosser brand, has made the best value in oral care even better with the launch of new 300-count value size packs of fan-favorite Micro Mint® and Twin-Line® varieties for a suggested retail price of $5.99 per pack. Micro Mint 300-count is now available for purchase at select Walmart, Meijer, Publix and Harmon Stores, while both Micro Mint and Twin-Line 300-count packs are available for purchase at Target nationwide.
Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be-reported quarter.
Perrigo Company plc (NYSE; TASE: PRGO) announced today that it has reached a definitive agreement to acquire the oral care assets of High Ridge Brands for $113 million in cash. The acquisition, which is subject to bankruptcy court approval in connection with High Ridge Brands' chapter 11 cases, as well as other customary closing conditions for this size of transaction, once again demonstrates Perrigo's commitment to transform to a consumer-focused self-care company and build shareholder value. The transaction is expected to close in the first quarter of 2020.
Readers hoping to buy Perrigo Company plc (NYSE:PRGO) for its dividend will need to make their move shortly, as the...
Perrigo (PRGO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality, Affordable Self-Care Products™", today announced that its Board of Directors, consistent with its transformation into a consumer self-care company, approved a 7% increase to the company's quarterly dividend to $0.225 per share from $0.21 per share. This dividend increase marks the 17th consecutive year Perrigo has increased its dividend.
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its fourth quarter and calendar year 2019 financial results on Thursday, February 27, 2020. The Company will also host a conference call beginning at 8:30 a.m. (EST).
Perrigo Company plc (NYSE: PRGO; TASE), a leading global provider of Quality, Affordable Self-Care Products™, today announced the future retirement of Jeff Needham, Executive Vice President and President, Consumer Self-Care Americas (CSCA). Rich Sorota, currently Chief Executive Officer and President of Ranir, will be appointed Executive Vice President and President, Consumer Self-Care Americas, on March 23, 2020, at which point Mr. Needham will step down from his current role and serve in an advisory role until his retirement on September 30, 2020.
Perrigo (PRGO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Teleflex (TFX) receives the FDA clearance for its bipolar temporary pacing guidewire, thus paving the way for improvements in TAVR and BAV procedures.
Shares of Perrigo Co. Plc rallied about 9% on Tuesday, after Leerink said sales guidance offered earlier in the day was strong. The company said it expects sales to total about $1.3 billion for the fourth quarter and $4.8 billion for the full year, both numbers above consensus. In a statement released ahead of an investor conference, the Dublin-based company said it had an "outstanding" fourth quarter. "All business segments delivered stellar fourth quarter net sales results with strong organic growth," the company said. Leerink analysts led by Ami Fadia said the numbers were "particularly strong even for the seasonally best quarter." Perrigo management are expected to offer further details at the conference around 4.30 Eastern time. The company is expected to release full fourth-quarter earnings in the fourth week of February. Leerink rates the stock market perform. Shares have gained 20% in the last 12 months, while the S&P 500 has gained 27%.
Perrigo Co. Plc said Tuesday it expects 2019 sales to come to $4.8 billion, up 2% from the year-earlier period and ahead of the $3.98 billion FactSet consensus. In a statement released ahead of an investor conference, the Dublin-based company said it had an "outstanding" fourth quarter. "All business segments delivered stellar fourth quarter net sales results with strong organic growth," the company said. Worldwide Consumer sales came to about $3.9 billion, up 2% from the year-earlier period. Consumer Self-Care Americas sales came to about $2.5 billion. Consumer Self-Care International sales came to about $1.4 billion, down 1%, while the drug segment sales came to about $970 million for a gain of about 5%. Shares rose 2.7% premarket and have gained about 10.5% in the last 12 months, while the S&P 500 has gained 27%.
Perrigo Company plc (NYSE: PRGO) (TASE: PRGO) Chief Executive Officer and President Murray S. Kessler will highlight the progress of the Company's transformation into a consumer self-care company and discuss certain financial metrics for recently completed periods later today at the 38th Annual J.P. Morgan Healthcare Conference.
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Perrigo Company plc...
Prominent securities litigation firm Bernstein Litowitz Berger & Grossmann LLP ("BLB&G;") announces a key victory in the securities class action against Perrigo Company plc ("Perrigo" or the "Company"), with the certification of three classes of investors by a New Jersey federal court.